dendreon corp (DNDN:NASDAQ GS)
John H. Johnson
Chief Executive Officer and President, Dendreon Corp.
|Age||Total Calculated Compensation||This person is connected to 43 board members in 3 different organizations across 10 different industries.|
See Board Relationships
As of Fiscal Year 2013
Mr. John H. Johnson is a Founder of The Atlantic Foundation. Mr. Johnson has been the Chief Executive Officer and President of Dendreon Corp. since February 2012. Mr. Johnson served as the Chief Executive Officer of Savient Pharmaceuticals, Inc. from January 31, 2011 to February 1, 2012 and served as its President until February 1, 2012. He served as the President and Head of Lilly Oncology (Oncology Business Unit) and Senior Vice President of Eli Lilly and Company from ...
1301 2nd AvenuePhone: 206-256-4545
Seattle, Washington 98101
Board Members Memberships*
Former Chief Executive Officer, President and Director
Former Chairman of the Board
Former President of Global Oncology Business Unit - Eli Lilly and Company
Director and Member of Nominating & Governance Committee
Chairman, Member of Audit Committee and Member of Nominating & Corporate Governance Committee
Chief Executive Officer and President
Director and Chairman of Compensation Committee
East Stroudsburg University
|Ron Squarer BSc (Biochemistry), MBA||Chief Executive Officer and Director|
Array BioPharma, Inc.
|James A. Bianco M.D.||Principal Founder, Chief Executive Officer, President, Executive Director, Member of Scientific Advisory Board and Member of Executive Committee|
CTI BioPharma Corp.
|Rajesh C. Shrotriya M.D.||Chairman, Chief Executive Officer, Chairman of Product Acquisition Committee and Chairman of Placement Committee|
Spectrum Pharmaceuticals, Inc.
|Aijaz Tobaccowalla||Managing Director, Additional Non-Executive Director, Member of Share Transfer Committee, Member of Audit Committee and Member of Shareholders' / Investors' Grievance Committee|
|Aijaz Tobaccowalla||Managing Director, Additional Director and Member of Board Administrative Committee|
|17.6M||Compensation as of Fiscal Year 2013.|